Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?

doi:10.3748/wjg.v27.i33.5536

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 33

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4858)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

484

WORD

132

HTML

2792

Tables (1-5)

227

Sum=3635

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

471

Download

751

Sum=1222

Sep 7, 2021 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Sep 7, 2021; 27(33): 5536-5554
Published online Sep 7, 2021. doi: 10.3748/wjg.v27.i33.5536

Table 5 Algorithmic approaches using the combination of serologic and clinical parameters for hepatocellular carcinoma risk prediction

Risk scores	Cohort: Patients/ratio of cirrhosis	Study population	Variables	External validation
GALAD score (Johnson et al[72], 2014)	HCC case: 670/90%; CLD control: 339/97%	Caucasian (England)	AFP; AFP-L3; DCP	Asian, Caucasian
Doylestown algorithm (Wang et al[76], 2016)	Training HCC case: 165/100%; CLD control: 195/100%; Validation 1 HCC case: 432/100%; CLD control: 438/100%; Validation 2 HCC case: 113/100%; CLD control: 586/100%; Validation 3 HCC case: 425/100%; CLD control: 804/100%	North America (United States)	Age; Gender; ALT; ALP; AFP; Fucosylated kininogen	North America (United States)
GALADUS score (Yang et al[75], 2019)	Training HCC case: 111/98%; CLD control: 180/85%; Validation HCC case: 233/100%; CLD control: 412/100%	North America (United States)	AFP; AFP-L3; DCP; Ultrasonography	North America (United States)
HES algorithm (Tayob et al[78,79], 2019)	HCC case: 4804/100%; CLD control: 33627/100%	North American (United States Veterans Administration)	Age; Rate of AFP change; ALT; Platelet count; Etiology of cirrhosis	-

AFP: Alpha-fetoprotein; AFP-L3: Alpha-fetoprotein-L3; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; DCP: Des-gamma-carboxy-prothrombin, HCC: Hepatocellular carcinoma; CLD: Chronic liver disease.

Citation: Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554
URL: https://www.wjgnet.com/1007-9327/full/v27/i33/5536.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i33.5536